← Leaderboards
Jin-Ming Yang
University Of Kentucky
$5,088,324
Attributed
$7,110,486
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $821.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,110,486 · 7
By mechanism
R01$6,335,371 · 5
R21$775,115 · 2
Top collaborators
- Jianxun Jim Song8 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Jianxun Jim Song$6,323,672
- Rina Plattner$6,723,029
- John A Dorazio$4,132,034
- Russell J Mumper$6,017,636
- Melissa A Wilson$780,548
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellResponseProteinsDesignTumorCessation Of LifeIn VitroMediatingCellsAffectNovel StrategiesPlayMalignant NeoplasmsInnovationMolecularRegulationCytotoxic T-LymphocytesNovel TherapeuticsImmuneLaboratoriesImmunotherapyNeoplasmsAdoptive Cell TransfersMelanoma
Grant awards (21)
Integrative Targeted Therapy for Melanoma$608,620
R01 · FY2025 · CA · contact PI
Novel Strategy to Augmenting Immunotherapy against Melanoma$212,993
R21 · FY2025 · CA · contact PI
Integrative Targeted Therapy for Melanoma$632,195
R01 · FY2024 · CA · contact PI
Novel Strategy to Augmenting Immunotherapy against Melanoma$177,259
R21 · FY2024 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$550,644
R01 · FY2023 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$550,643
R01 · FY2022 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$561,881
R01 · FY2021 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$562,597
R01 · FY2020 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$417,630
R01 · FY2018 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$160,114
R01 · FY2018 · CA · contact PI
Autophagy in Brain Tumor$304,364
R01 · FY2013 · CA · contact PI
Autophagy in Brain Tumor$323,791
R01 · FY2012 · CA · contact PI
Autophagy in Brain Tumor$323,791
R01 · FY2011 · CA · contact PI
Autophagy in Brain Tumor$333,456
R01 · FY2010 · CA · contact PI
Autophagy in Brain Tumor$332,771
R01 · FY2009 · CA · contact PI
Regulation of Multidrug Resistance Phenotype$164,856
R01 · FY2007 · CA · contact PI
Regulation of Multidrug Resistance Phenotype$54,811
R01 · FY2007 · CA · contact PI
Regulation of Multidrug Resistance Phenotype$227,769
R01 · FY2006 · CA · contact PI
Drug Sensitivity of Calcium Modulators from Brain Tumor$225,438
R01 · FY2006 · CA · contact PI
role of ubiquitinin in cancer progression$209,925
R21 · FY2005 · CA
role of ubiquitin in cancer progression$174,938
R21 · FY2004 · CA